Optimising delivery of care in coeliac disease - Comparison of the benefits of repeat biopsy and serological follow-up

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 10, 2013, Pages 1278-1291

  Sharkey, L M ^a   Corbett, G ^a   Currie, E ^a   Lee, J ^a   Sweeney, N ^b   Woodward, J M ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOMYSIUM ANTIBODY; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CELIAC DISEASE; CHILD; COHORT ANALYSIS; DIETARY COMPLIANCE; FEMALE; FOLLOW UP; GASTROINTESTINAL BIOPSY; GLUTEN FREE DIET; HEALTH CARE DELIVERY; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; INFANT; INTERMETHOD COMPARISON; INTESTINE VILLUS ATROPHY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; REPEAT PROCEDURE; RETROSPECTIVE STUDY; SCHOOL CHILD; SEROLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ATROPHY; BIOPSY; CELIAC DISEASE; CHILD; CHILD, PRESCHOOL; DELIVERY OF HEALTH CARE; DIET, GLUTEN-FREE; FEMALE; FOLLOW-UP STUDIES; GLUTENS; GTP-BINDING PROTEINS; HUMANS; INFANT; INTESTINAL MUCOSA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TRANSGLUTAMINASES; YOUNG ADULT;

EID: 84885948970     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12510     Document Type: Article

References (79)

1. Green PH, Cellier C,. Celiac disease. N Engl J Med 2007; 357: 1731-43.
2. Schuppan D, Junker Y, Barisani D,. Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009; 137: 1912-33.
3. Ludvigsson JF, Green PH,. Clinical management of coeliac disease. J Intern Med 2011; 269: 560-71.
4. Haines ML, Anderson RP, Gibson PR,. Systematic review: the evidence base for long-term management of coeliac disease. Aliment Pharmacol Ther 2008; 28: 1042-66.
5. Ciclitira PJ, Dewar DH, McLaughlin SD, Sanders DS,. The management of adults with coeliac disease. Brit Soc Gastroenterol 2010. Available at: http://www.bsg.org.uk/images/stories/clinical/bsg-coeliac-10.pdf.
6. Rostom A, Murray JA, Kagnoff MF,. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006; 131: 1981-2002.
7. Bai JC, Fried M, Corrazza GR, et al,. World Gastroenterology Organisation global guidelines on Coeliac Disease. J Clin Gastroenterol 2013; 47: 121-6.
8. Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA,. ACG clinical guidelines: diagnosis and management of Coeliac Disease. Am J Gastroenterol 2013; 108: 656-76.
9. Herman ML, Rubio-Tapia A, Lahr BD, Larson JJ, Van Dyke CT, Murray JA,. Patients with celiac disease are not followed up adequately. Clin Gastro-enterol Hepatol 2012; 10: 893-9; e1.
10. Silvester J, Rashid M,. Long-term management of patients with celiac disease: current practices of gastroenterologists in Canada. Can J Gastroenterol 2010; 24: 499-509.
11. Ciacci C, Cirillo M, Cavallaro R, Mazzacca G,. Long-term follow-up of celiac adults on gluten-free diet: prevalence and correlates of intestinal damage. Digestion 2002; 66: 178-85.
12. Leffler DA, Dennis M, Edwards George JB, et al,. A simple validated gluten-free diet adherence survey for adults with celiac disease. Clin Gastroenterol Hepatol 2009; 7: 530-6.
13. Biagi F, Bianchi PI, Marchese A, et al,. A score that verifies adherence to a gluten-free diet: a cross-sectional, multicentre validation in real clinical life. Br J Nutr 2012; 108: 1884-8.
14. Vecsei AK, Graf UB, Vogelsang H,. Follow-up of adult celiac patients: which noninvasive test reflects mucosal status most reliably? Endoscopy 2009; 41: 123-8.
15. Bebb JR, Lawson A, Knight T, Long RG,. Long-term follow-up of coeliac disease-what do coeliac patients want? Aliment Pharmacol Ther 2006; 23: 827-31.
16. Mayer M, Greco L, Troncone R, Auricchio S, Marsh MN,. Adherence of adolescents with coeliac disease with a gluten free diet. Gut 1991; 32: 881-5.
17. Hall NJ, Rubin G, Charnock A,. Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease. Aliment Pharmacol Ther 2009; 30: 315-30.
18. Bardella MT, Molteni N, Prampolini L, et al,. Need for follow up in coeliac disease. Arch Dis Child 1994; 70: 211-3.
19. Ljungman G, Myrdal U,. Adherence in teenagers with coeliac disease-a Swedish follow-up study. Acta Paediatr 1993; 82: 235-8.
20. Kolsteren MM, Koopman HM, Schalekamp G, Mearin ML,. Health-related quality of life in children with celiac disease. J Pediatr 2001; 138: 593-5.
21. Jacobsson LR, Friedrichsen M, Goransson A, Hallert C,. Impact of an active patient education program on gastrointestinal symptoms in women with celiac disease following a gluten-free diet: a randomized controlled trial. Gastroenterol Nurs 2012; 35: 200-6.
22. Ravelli A, Bolognini S, Gambarotti M, Villanacci V,. Variability of histologic lesions in relation to biopsy site in gluten-sensitive enteropathy. Am J Gastroenterol 2005; 100: 177-85.
23. Marsh MN,. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology 1992; 102: 330-54.
24. Oberhuber G, Granditsch G, Vogelsang H,. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 1999; 11: 1185-94.
25. Corazza GR, Villanacci V,. Coeliac disease. J Clin Pathol 2005; 58: 573-4.
26. WHO. Available at: http://www.codexalimentarius.org/download/standards/ 291/cxs-118e.pdf, 2008.
27. Lo W, Sano K, Lebwohl B, Diamond B, Green PH,. Changing presentation of adult celiac disease. Dig Dis Sci 2003; 48: 395-8.
28. Reilly NR, Fasano A, Green PH,. Presentation of celiac disease. Gastrointest Endosc Clin N Am 2012; 22: 613-21.
29. Casella S, Zanini B, Lanzarotto F, Villanacci V, Ricci C, Lanzini A,. Celiac disease in elderly adults: clinical, serological, and histological characteristics and the effect of a gluten-free diet. J Am Geriatr Soc 2012; 60: 1064-9.
30. Murray JA, Watson T, Clearman B, Mitros F,. Effect of a gluten-free diet on gastrointestinal symptoms in celiac disease. Am J Clin Nutr 2004; 79: 669-73.
31. Kluge F, Koch HK, Grosse-Wilde H, Lesch R, Gerok W,. Follow-up of treated adult celiac disease: clinical and morphological studies. Hepatogastroenterology 1982; 29: 17-23.
32. Rubio-Tapia A, Kyle RA, Kaplan EL, et al,. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology 2009; 137: 88-93.
33. Godfrey JD, Brantner TL, Brinjikji W, et al,. Morbidity and mortality among older individuals with undiagnosed celiac disease. Gastroenterology 2010; 139: 763-9.
34. Viljamaa M, Kaukinen K, Pukkala E, Hervonen K, Reunala T, Collin P,. Malignancies and mortality in patients with coeliac disease and dermatitis herpetiformis: 30-year population-based study. Dig Liver Dis 2006; 38: 374-80.
35. Howdle PD, Jalal PK, Holmes GK, Houlston RS,. Primary small-bowel malignancy in the UK and its association with coeliac disease. QJM 2003; 96: 345-53.
36. Lahdeaho ML, Maki M, Laurila K, Huhtala H, Kaukinen K,. Small- bowel mucosal changes and antibody responses after low- and moderate-dose gluten challenge in celiac disease. BMC Gastroenterol 2011; 11: 129.
37. Rubio-Tapia A, Rahim MW, See JA, Lahr BD, Wu TT, Murray JA,. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. Am J Gastroenterol 2010; 105: 1412-20.
38. Wahab PJ, Meijer JW, Mulder CJ,. Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. Am J Clin Pathol 2002; 118: 459-63.
39. Hutchinson JM, West NP, Robins GG, Howdle PD,. Long-term histological follow-up of people with coeliac disease in a UK teaching hospital. QJM 2010; 103: 511-7.
40. Lanzini A, Lanzarotto F, Villanacci V, et al,. Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Aliment Pharmacol Ther 2009; 29: 1299-308.
41. Lebwohl B, Granath F, Ekbom A, et al,. Mucosal healing and mortality in coeliac disease. Aliment Pharmacol Ther 2013; 37: 332-9.
42. Ludvigsson JF, Montgomery SM, Ekbom A, Brandt L, Granath F,. Small-intestinal histopathology and mortality risk in celiac disease. JAMA 2009; 302: 1171-8.
43. Kurppa K, Collin P, Sievanen H, Huhtala H, Maki M, Kaukinen K,. Gastrointestinal symptoms, quality of life and bone mineral density in mild enteropathic coeliac disease: a prospective clinical trial. Scand J Gastroenterol 2010; 45: 305-14.
44. Dickey W, Hughes DF, McMillan SA,. Reliance on serum endomysial antibody testing underestimates the true prevalence of coeliac disease by one-fifth. Scand J Gastroenterol 2000; 35: 181-3.
45. Hopper AD, Hadjivassiliou M, Hurlstone DP, et al,. What is the role of serologic testing in celiac disease? A prospective, biopsy-confirmed study with economic analysis Clin Gastroenterol Hepatol 2008; 6: 314-20.
46. Salmi TT, Collin P, Korponay-Szabo IR, et al,. Endomysial antibody-negative coeliac disease: clinical characteristics and intestinal autoantibody deposits. Gut 2006; 55: 1746-53.
47. Boger CP, Thomas PW, Nicholas DS, Surgenor SL, Snook JA,. Determinants of endomysial antibody status in untreated coeliac disease. Eur J Gastroenterol Hepatol 2007; 19: 890-5.
48. Leffler D, Schuppan D, Pallav K, et al,. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut 2013; 62: 996-1004.
49. Dickey W, Hughes DF, McMillan SA,. Disappearance of endomysial antibodies in treated celiac disease does not indicate histological recovery. Am J Gastroenterol 2000; 95: 712-4.
50. Dipper CR, Maitra S, Thomas R, et al,. Anti-tissue transglutaminase antibodies in the follow-up of adult coeliac disease. Aliment Pharmacol Ther 2009; 30: 236-44.
51. Tursi A, Brandimarte G, Giorgetti GM,. Lack of usefulness of anti-transglutaminase antibodies in assessing histologic recovery after gluten-free diet in celiac disease. J Clin Gastroenterol 2003; 37: 387-91.
52. Nachman F, Sugai E, Vazquez H, et al,. Serological tests for celiac disease as indicators of long-term adherence with the gluten-free diet. Eur J Gastroenterol Hepatol 2011; 23: 473-80.
53. Sugai E, Nachman F, Vaquez H, et al,. Dynamics of celiac disease-specific serology after initiation of a gluten-free diet and use in the assessment of adherence with treatment. Dig Liver Dis 2010; 42: 352-8.
54. National Institute for Health and Clinical Excellence. Coeliac Disease: Recognition and Assessment of Coeliac Disease. London: National Institute for Health and Clinical Excellence, 2009. Available at: http://www.nice.org.uk/CG86.
55. Selby WS, Painter D, Collins A, Faulkner-Hogg KB, Loblay RH,. Persistent mucosal abnormalities in coeliac disease are not related to the ingestion of trace amounts of gluten. Scand J Gastroenterol 1999; 34: 909-14.
56. Kaukinen K, Salmi T, Collin P, Huhtala H, Karja-Lahdensuu T, Maki M,. Clinical trial: gluten microchallenge with wheat-based starch hydrolysates in coeliac disease patients-a randomized, double-blind, placebo-controlled study to evaluate safety. Aliment Pharmacol Ther 2008; 28: 1240-8.
57. Peraaho M, Kaukinen K, Paasikivi K, et al,. Wheat-starch-based gluten-free products in the treatment of newly detected coeliac disease: prospective and randomized study. Aliment Pharmacol Ther 2003; 17: 587-94.
58. Kaukinen K, Collin P, Holm K, et al,. Wheat starch-containing gluten-free flour products in the treatment of coeliac disease and dermatitis herpetiformis. A long-term follow-up study. Scand J Gastroenterol 1999; 34: 163-9.
59. Collin P, Thorell L, Kaukinen K, Maki M,. The safe threshold for gluten contamination in gluten-free products. Can trace amounts be accepted in the treatment of coeliac disease? Aliment Pharmacol Ther 2004; 19: 1277-83.
60. Hischenhuber C, Crevel R, Jarry B, et al,. Review article: safe amounts of gluten for patients with wheat allergy or coeliac disease. Aliment Pharmacol Ther 2006; 23: 559-75.
61. Collin P, Maki M, Kaukinen K,. Safe gluten threshold for patients with celiac disease: some patients are more tolerant than others. Am J Clin Nutr 2007; 86: 260; author reply 60-1.
62. Faulkner-Hogg KB, Selby WS, Loblay RH,. Dietary analysis in symptomatic patients with coeliac disease on a gluten-free diet: the role of trace amounts of gluten and non-gluten food intolerances. Scand J Gastroenterol 1999; 34: 784-9.
63. Lee SK, Lo W, Memeo L, Rotterdam H, Green PH,. Duodenal histology in patients with celiac disease after treatment with a gluten-free diet. Gastrointest Endosc 2003; 57: 187-91.
64. Grefte JM, Bouman JG, Grond J, Jansen W, Kleibeuker JH,. Slow and incomplete histological and functional recovery in adult gluten sensitive enteropathy. J Clin Pathol 1988; 41: 886-91.
65. Catassi C, Fabiani E, Iacono G, et al,. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr 2007; 85: 160-6.
66. Ludvigsson JF, Leffler DA, Bai JC, et al,. The Oslo definitions for coeliac disease and related terms. Gut 2013; 62: 43-52.
67. Brar P, Kwon GY, Egbuna II, et al,. Lack of correlation of degree of villous atrophy with severity of clinical presentation of coeliac disease. Dig Liver Dis 2007; 39: 26-9.
68. Kaukinen K, Peraaho M, Lindfors K, et al,. Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease. Aliment Pharmacol Ther 2007; 25: 1237-45.
69. Al-Toma A, Verbeek WH, Hadithi M, von Blomberg BM, Mulder CJ,. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut 2007; 56: 1373-8.
70. Rubio-Tapia A, Kelly DG, Lahr BD, Dogan A, Wu TT, Murray JA,. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 2009; 136: 99-107.
71. Malamut G, Afchain P, Verkarre V, et al,. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology 2009; 136: 81-90.
72. Roshan B, Leffler DA, Jamma S, et al,. The incidence and clinical spectrum of refractory celiac disease in a north american referral center. Am J Gastroenterol 2011; 106: 923-8.
73. Jones R, Hunt C, Stevens R, et al,. Management of common gastrointestinal disorders: quality criteria based on patients' views and practice guidelines. Br J Gen Pract 2009; 59: e199-208.
74. Green PH, Neugut AI, Naiyer AJ, Edwards ZC, Gabinelle S, Chinburapa V,. Economic benefits of increased diagnosis of celiac disease in a national managed care population in the United States. J Insur Med 2008; 4: 218-28.
75. Violato M, Gray A, Papanicolas I, Ouellet M,. Resource use and costs associated with coeliac disease before and after diagnosis in 3,646 cases: results of a UK primary care database analysis. PLoS ONE 2012; 7: e41308.
76. Long KH, Rubio-Tapia A, Wagie AE, et al,. The economics of coeliac disease: a population-based study. Aliment Pharmacol Ther 2010; 32: 261-9.
77. Elfström P, Granath F, Ekström Smedby K, et al,. Risk of lymphoproliferative malignancy in relation to small intestinal histopathology among patients with celiac disease. J Natl Cancer Inst. 2011; 103: 436-44.
78. Lebwohl B, Granath F, Ekbom A, et al,. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study. Ann Intern Med 2013; 159: 169-75.
79. Derikx JP, Vreugdenhil AC, Van den Neucker AM, et al,. A pilot study on the noninvasive evaluation of intestinal damage in celiac disease using I-FABP and L-FABP. J Clin Gastroenterol 2009; 43: 727-33.